Tharimmune Balance Sheet Health

Financial Health criteria checks 4/6

Tharimmune has a total shareholder equity of $3.0M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $5.3M and $2.2M respectively.

Key information

0%

Debt to equity ratio

US$0

Debt

Interest coverage ration/a
CashUS$4.77m
EquityUS$3.02m
Total liabilitiesUS$2.23m
Total assetsUS$5.25m

Recent financial health updates

Is Hillstream BioPharma (NASDAQ:HILS) In A Good Position To Invest In Growth?

Feb 14
Is Hillstream BioPharma (NASDAQ:HILS) In A Good Position To Invest In Growth?

Recent updates

Is Hillstream BioPharma (NASDAQ:HILS) In A Good Position To Invest In Growth?

Feb 14
Is Hillstream BioPharma (NASDAQ:HILS) In A Good Position To Invest In Growth?

Financial Position Analysis

Short Term Liabilities: THAR's short term assets ($5.3M) exceed its short term liabilities ($2.2M).

Long Term Liabilities: THAR has no long term liabilities.


Debt to Equity History and Analysis

Debt Level: THAR is debt free.

Reducing Debt: THAR had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: THAR has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: THAR has less than a year of cash runway if free cash flow continues to reduce at historical rates of 43.5% each year


Discover healthy companies